rologie i - European Congress of Virology

Recommendations

Info

5 th European Congress of Virology04. ADAPTIVE IMMUNITY ANDVACCINESPosters: REF 037 to REF 061REF 037Nanocomplexes as delivery system for vaccine preparationsMadina ABITAYEVA 1 , Pavel ALEXUYK 1 , AizhanTURMAGAMBETOVA 1 , Irina ZAITSEVA 1 , AndreyBOGOYAVLENSKIY 1 , Vladimir BEREZIN 1Institute of microbiology and virology, Almaty, KAZAKHSTANIn recent years to increase the efficiency subunit vaccines have startedthe development using the principles of nanotechnology. The inclusion ofadjuvants with different structures (liposomes, nanosomes, sferosomes,protein complexes, etc.) in compound of subunit vaccine can greatlyincrease the immunogenicity of antigens, balanced induce componentsof cellular and humoral immune response. The most perspective is use ofthe virus like nanoparticles derived from plant saponins, with low toxicityand high immunogenic activity. In this research, has been tasked to studythe immunogenic and protective activity at animal immunization of wholevirion inactivated virus in combination with the immunostimulatory nanocomplexesobtained on the basis of saponins extracted from the plants ofthe flora of Kazakhstan.To study the immunogenic and protective activity of received preparationanimals were immunized with different strains of inactivated influenzavirus in combination with immunostimulatory nanoparticles obtained onthe basis of plant saponins. Immunogenicity was evaluated by titer ofimmunoglobulins and interleukins in the blood serum one week aftersecond immunization. The protective activity of the preparations was evaluatedby the number of surviving animals after experimental infection.Studies have shown that immunization of mice with immunostimulatorynanocomplexes in the presence of viral antigen leads to the induction ofhumoral and cellular immune responses. Stimulation of the immune responseoccurs even with whole virione vaccines based on influenza virusesH5N1 and H1N1, derived by reverse genetics. Were established the highprotective activity of immunostimulating complex against virus infectionsin vaccinated animals of different ages, capable of vertical transmission.The need to improve immunogenicity of current influenza vaccines,especially in elderly people, have led to the licensure of two new “implementedvaccines” for people aged =65 years: Fluad (MF59 adjuvantedsubunit vaccine) and Intanza 15 g (split non adjuvanted intradermal vaccine).The aim of our study was to compare the immunogenicity of thetwo implemented vaccines commercially available for the Winter season2012/13 (A/California/7/09 (H1N1), A/Victoria/361/11 (H3N2) andB/Wisconsin/1/10). A total of 172 elderly (mean age 86 years) chronicallyill volunteers living in nursing homes located in Umbria, Italy, wererandomly assigned to receive one dose of either Fluad (N. 92) or Intanza(N. 80). Haemagglutination inhibiting (HI) antibody titers were determinedin blood samples collected before and 1 month after vaccination. Theresults obtained showed that both vaccines were able to induce increases inthe amount of HI antibodies against all the three vaccine strains, althoughthe three immunogenicity criteria of European Medicine Agency werenot always satisfied. Non inferiority of Intanza was demonstrated forall strains (ratios [Fluad/Intanza] of post vaccination Geometric MeanTiters were always
5 th European Congress of Virologyfirst expanded by DNA vaccination of the recipient mice. We characterizedspleen derived T lymphocyte cytokine responses to different peptides.The WNV structural proteins were expressed as a series of overlapping 20mer peptides fused to a carrier protein. Cytokine based ELISPOT assaysrevealed that peptides are recognized by T cells recovered directly ex vivofrom vaccinated animals.REF 041High hydrostatic pressure effect on the epitope mapping of the tobaccomosaic virus coat proteinDaniel FERREIRA DE LIMA NETO 1,2 , Clarice WEIS ARNS 1 , CarlosFRANCISCO SAMPAIO BONAFÉ 21 Instituto de Biologia/Departamento de Microbiologia/UniversidadeEstadual de Campinas, Campinas, BRASIL; 2 Instituto de Biologia/Departamentode Bioquímica/Universidade Estadual de Campinas,Campinas, BRASILThis study was aimed to investigate the effect of high hydrostatic pressureon Tobacco Mosaic Virus (TMV), a virus model for immunologyand one of the most studied virus to date. When subjected to treatmentwith pressures it was observed a significant change in the recognized epitopesin comparison to sera from immunized mice with the native formof the virus. These alterations were further studied by combining the highpressure treatment with urea or low temperatures and inoculation of thesealtered virions in Balb C mice, the collected sera titers were determined byELISA and cross referenced between the groups tested. The titter obtainedshowed that the antigenicity of viral particles was maintained after treatmentsusing monoclonal antibodies against the native form. The epitopeprediction algorithms could not infer the some observed changes in theepitope profile suggesting conformational changes in the protein structure.The antigenicity of canonical epitopes was maintained, although bindingintensities were different among the treatments used. Patterns of recognitionfrom the epitope mapping were then cross checked with the predictionalgorithms for the TMVcp amino acid sequence to infer which alterationsmight have occurred. Our findings suggest that different cleavages siteswere exposed after the treatments; this was verified via epitope mappingusing sera from mice immunized with the virus after the high pressurecondition was imposed.REF 042Surface Display of Foot and Mouth Disease Virus Recombinant Proteinin Escherichia coliSoheil HADJI KHODADAD 1 , Gholamreza AHMADIAN 1 , MehdiSHAMS ARA 1 , Mona KARBALAYI 2 , Sahar SEDDIGHZADEH 11 NIGEB, Department of Biotechnology, Tehran, IRAN; 2 Tarbiat ModarresUniversity, Department of Medical Bacteriology, Tehran, IRANEmergency vaccines designed to protect livestock against FMDV are quiteeffective; however, they do little to induce mucosal immunity. The absenceof mucosal immunity allows for the establishment of sub clinical infections,the generation of carrier animals, and ultimately in the emergenceof escape mutants. This project used synthetic peptides, administeredorally to induce secretory immunity in the gastrointestinal tract of cattle.Methods: Several different FMDV peptides containing the immunogenicregion of VP1 were expressed on the surface of E.coli. These peptidesthen administered orally. Systemic and mucosal antibody production wasevaluated. Results: The immunogenicity of the VP1 epitopes expressed inthe recombinant E.coli was tested by immunizing cattle. Ten days after thelast inoculation, animals were bled and the sera analyzed for the presenceof anti FMDV antibodies by ELISA and Western blot. The results indicatedthat all the sera from the VP1 immunized cattle presented a specificantibody response against FMDV VP1 antigen. The anti VP1 specificityof the antibody response in the sera of the vaccinated cattle was furtherconfirmed by Western blot using purified inactivated FMDV as antigen.Conclusions: These results demonstrated the possibility of using a noveland simple, methodology for obtaining high levels of foreign immunogenicepitopes which could be directly applied in the development ofveterinary medicine vaccine. Additional studies will be performed usingnovel synthetic peptides designed to block the attachment of the virus toGIT epithelial cells.REF 043Variation in the fine specificity of the human antibody response afternatural infection or vaccination with tick borne encephalitis virus(TBEV)Johanna JARMER 1 , Jürgen ZLATKOVIC 1 , GeorgiosTSOUCHNIKAS 1 , Judith H. ABERLE 1 , Vaclav CHMELIK 2 , KarinSTIASNY 1 , Franz X. HEINZ 11 Department of Virology/Medical University of Vienna, Vienna, AUSTRIA;2 Department of Infectious Diseases/Hospital Ceske Budejovice, CeskeBudejovice, CZECH REPUBLICIndividual specific variations in the fine specificity of polyclonal serumantibody (Ab) responses are incompletely understood aspects of humoralimmunity that can have a strong influence on functional activity. Weaddressed this issue in the context of TBEV, one of the major humanpathogenic flaviviruses, both after natural infection and vaccination withthe purified formalin inactivated whole virus vaccine. The envelopeprotein E is the major target of neutralizing Abs and contains 3 structuraldomains: DI, DII and DIII. We made use of the modular organization ofE and established immunoassays with recombinant proteins that allowedus the quantification of Abs to each of the domains of E, as well as prM(found in immature virions) and broadly flavivirus cross reactive epitopes.Both after infection and vaccination, extensive individual differenceswere observed in the composition of domain specific Abs. However, inboth groups the humoral response is dominated by Abs to DII, whereasthe more strongly neutralizing DIII reactive Abs are underrepresented.Post infection sera showed a significantly higher neutralization potentialand a stronger prM response, while those after vaccination containedmore broadly flavivirus cross reactive Abs. Our results suggest that serumAb fine specificity is not only subject to strong individual variation, butalso differs when the virus is presented to the immune system in thecourse of replication or in an inactivated form.REF 044Identification of linear human B cell epitopes of tick borne encephalitisvirusSuvi KUIVANEN 1 , Jussi HEPOJOKI 1 , Antti VAHERI 1,3 , OlliVAPALAHTI 1,2,31 Haartman Institute, Helsinki, FINLAND; 2 Department of Basic VeterinarySciences, Helsinki, FINLAND; 3 HUSLAB, Helsinki, FINLANDTick borne encephalitis (TBE) is a neurological disease transmitted tohumans by ticks. It is endemic in many European countries, Russia andChina. The causative agent, tick borne encephalitis virus (TBEV), belongsto the family Flaviviridae, a group of globally important arthropod borneviruses, such as dengue, Yellow fever, Japanese encephalitis and West Nilevirus. The flavivirus genome is approximately 11 kilobases long singlestranded positive sense RNA. The virion consists of the three structuralproteins (C, prM and E), the positive sense RNA genome and a lipid membranederived from the host cell. The seven nonstructural proteins (NS1,NS2A, NS2B, NS3, NS4A, NS4B and NS5) are found in the infected celland most of them function at least in genome replication. The structuralprotein E is known to raise protective neutralizing antibody responses. Ithas been shown with other flaviviruses that also NS1 can elicit protectiveimmune responses. Linear epitope mapping has been carried out with otherS130 Virologie, Vol 17, supplément 2, septembre 2013
Page 3 and 4:
Contents5 th European Congress of V
Page 5 and 6:
i r o l o g i eList of Keynote Spea
Page 7 and 8:
i r o l o g i eList of Chairpersons
Page 9 and 10:
i r o l o g i eWelcomeWelcome to th
Page 11 and 12:
5 th European Congress of VirologyY
Page 13 and 14:
i r o l o g i eExhibitorsThe indust
Page 15:
i r o l o g i eFacilities for the 5
Page 18 and 19:
i r o l o g i eGeneral Information
Page 20 and 21:
PROGRAMME AT A GLANCEWednesday 11th
Page 22 and 23:
5 th European Congress of VirologyW
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Scientific Programme -Saturday 14 t
Page 34 and 35:
5 th European Congress of Virology1
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
5 th European Congress of VirologyT
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
5 th European Congress of VirologyR
Page 56 and 57:
Page 58 and 59:
5 th European Congress of Virologyw
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
5 th European Congress of Virologyt
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
5 th European Congress of VirologyA
Page 72 and 73:
5 th European Congress of Virologyp
Page 74 and 75:
Page 76 and 77:
5 th European Congress of VirologyF
Page 78 and 79:
5 th European Congress of VirologyF
Page 80 and 81: 5 th European Congress of Virologyc
Page 82 and 83: 5 th European Congress of VirologyF
Page 86 and 87: 5 th European Congress of Virologyt
Page 88 and 89: 5 th European Congress of VirologyH
Page 92 and 93: 5 th European Congress of VirologyR
Page 96 and 97: 5 th European Congress of VirologyS
Page 104 and 105: 5 th European Congress of VirologyA
Page 106 and 107: 5 th European Congress of Virology1
Page 118 and 119: Virologie 2013, 17 (supplément 2)
Page 126 and 127: 5 th European Congress of VirologyH
Page 128 and 129: 5 th European Congress of Virologys
Page 132 and 133: 5 th European Congress of Virologyf
Page 134 and 135: 5 th European Congress of VirologyE
Page 140 and 141: 5 th European Congress of Virologyp
Page 144 and 145: 5 th European Congress of Virologyi
Page 146 and 147: 5 th European Congress of Virologyr
Page 150 and 151: 5 th European Congress of Virologyp
Page 160 and 161: 5 th European Congress of VirologyB
Page 162 and 163: 5 th European Congress of Virologyr
Page 168 and 169: 5 th European Congress of VirologyI
Page 170 and 171: 5 th European Congress of Virologyf
Page 172 and 173: 5 th European Congress of Virologya
Page 180 and 181:
5 th European Congress of VirologyV
Page 182 and 183:
5 th European Congress of Virologyc
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
5 th European Congress of Virologya
Page 190 and 191:
Page 192 and 193:
5 th European Congress of Virologyn
Page 194 and 195:
5 th European Congress of Virologyi
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
5 th European Congress of Virology(
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
5 th European Congress of Virologyo
Page 208 and 209:
5 th European Congress of VirologyI
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
5 th European Congress of Virology(
Page 224 and 225:
Page 226 and 227:
5 th European Congress of Virologyn
Page 228 and 229:
Page 230 and 231:
5 th European Congress of Virologyo
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
5 th European Congress of Virologyc
Page 246 and 247:
Page 248 and 249:
5 th European Congress of Virologyh
Page 250 and 251:
Page 252 and 253:
5 th European Congress of VirologyC
Page 254 and 255:
5 th European Congress of VirologyM
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
5 th European Congress of Virologyf
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
5 th European Congress of VirologyM
Page 268 and 269:
Page 270 and 271:
Page 272 and 273:
5 th European Congress of Virologyu
Page 274 and 275:
5 th European Congress of VirologyO
Page 276 and 277:
5 th European Congress of Virologys
Page 278 and 279:
Page 280 and 281:
5 th European Congress of Virologyf
Page 282 and 283:
Page 284 and 285:
Page 286 and 287:
Page 288 and 289:
5 th European Congress of VirologyB
Page 290 and 291:
5 th European Congress of VirologyD
Page 292 and 293:
5 th European Congress of VirologyG
Page 294 and 295:
5 th European Congress of VirologyJ
Page 296 and 297:
5 th European Congress of VirologyL
Page 298 and 299:
5 th European Congress of VirologyN
Page 300 and 301:
Page 302 and 303:
5 th European Congress of VirologyS
Page 304 and 305:
show all

rologie i - European Congress of Virology

Create successful ePaper yourself

Delete template?

Save as template?